EUVIMED · CrossrefJournal
European Journal of Cancer
ISSN 0959-8049 · Elsevier BV
Latest articles
Letter Re: Assessing the magnitude of surveillance bias in prostate cancer, melanoma and lung cancer
Personalized biomarker-based treatment strategy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Results of the biomarker-driven cohorts of the EORTC-HNCG-1559 trial (UPSTREAM)
Circulating tumor DNA-guided therapeutic strategies for metastatic colorectal cancer patients with multiple small pulmonary-limited nodules: A prospective cohort study
Drugging the luminal axis end to end: A review of next-generation endocrine and targeted therapies in HR + /HER2- metastatic breast cancer
Multimodal treatment of isolated leptomeningeal relapse in BRAF-mutated dMMR colon cancer
Broadening the tumor antigens panorama for cancer vaccines – All the way to the dark matter of the genome
Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?
From staging to changing strategy: [18F]FDG PET/MRI’s impact on treatment planning in early breast cancer
Computational image features of immune architecture reveal molecular patterns associated with outcome and risk of recurrence in microsatellite-stable or MSI-low colon cancers
Radical local treatment for patients with NSCLC following oligoprogression after chemoradiation and durvalumab
Preventing progression to reduce costs: A cost-effectiveness analysis of enfortumab vedotin+pembrolizumab in MIBC
Osteosarcoma as a second or later malignancy: Presentation, treatment, and survival of 198 patients from the Cooperative Osteosarcoma Study Group
PELICAN-IPC 2015–016/Oncodistinct-003: A randomized non-comparative phase II study of pembrolizumab in combination with neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer
Cytokine release syndrome across three immunotherapy platforms: A real-world patient-level comparison of CAR T-cell, T-cell engager, and immune checkpoint inhibitor therapies
Efficacy and safety of chimeric antigen receptor T-cell therapy versus standard treatment in hemato-oncology: A systematic review and meta-analysis
Novel adenoma-immune phenotypes are associated with risk of metachronous polyps and colorectal cancer in a bowel screening cohort
Vitamin D supplementation, cancer incidence and mortality: Randomized trials revisited
Liver cancer incidence trends in younger versus older adults over time: an analysis of population-based cancer registry data
Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial
Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study
Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study
The UK’s radiotherapy workforce shortage: Reforming regulation to address the gap
Prophylactic use of G-CSFs to reduce neutropenia rates in patients treated with antibody–drug conjugates: A literature review
Corrigendum to “MRI in advanced ovarian cancer: Multicentre MISSION trial” [Eur J Cancer 238 (2026) 116614]
Corrigendum to “Molecular determinants of survival in metastatic uveal melanoma: The impact of SF3B1 mutations” Eur J Cancer 226 (August) (2025) 115591
Tumour-first DNA testing as a gateway to germline screening in patients with metastatic prostate cancer
Patient willingness to de-escalate adjuvant therapy based on predictive biomarker results in stage IIB-IIID melanoma: A cross-sectional survey
Corrigendum to “Incidence and survival of primary bone sarcoma diagnosed in England between 1996 and 2020; An analysis from the National Disease Registration Service” [Eur J Cancer 246 (October) (2026) 116981]
A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018)
Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary?
Volumes
2026 · 3492025 · 6862024 · 1,3682023 · 5292022 · 1,2002021 · 7082020 · 9522019 · 5572018 · 1,0062017 · 1,0862016 · 1,6782015 · 2,4802014 · 2,2082013 · 6662012 · 2,8222011 · 2,9712010 · 4442009 · 5272008 · 3882007 · 3882006 · 4732005 · 4292004 · 4872003 · 4422002 · 1,6802001 · 2,4922000 · 4231999 · 1,9101998 · 1,1681997 · 2,3651996 · 1,0041995 · 2,1321994 · 7741993 · 2,2111992 · 518
EUVIMED